
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc. has demonstrated promising results with its product candidate KSI-101, showing significant vision improvements and high rates of retinal dryness in a substantial majority of patients by Week 8. The company's tarcocimab has also achieved all secondary endpoints in clinical trials, evidencing a notable reduction in sight-threatening complications, thereby supporting confidence in its potential market impact. Together with progressive advancements in its pipeline and positive feedback from retinal key opinion leaders (KOLs), these factors contribute to a favorable outlook for Kodiak Sciences' stock.
Bears say
Kodiak Sciences Inc has encountered significant challenges with its product candidates, specifically marked by multiple trial failures, including the Phase 3 GLEAM and GLIMMER trials in DME and the Phase 2b/3 DAZZLE trial in wet AMD. The company reported a notable net loss of $61.5 million, equating to $1.16 per diluted share for the third quarter of 2025, raising concerns over its financial health. Additionally, substantial risks are associated with the company's ability to secure necessary capital and achieve expected commercial revenue from its pipeline products, further supporting a negative outlook.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares